The application of Glycoprotein IIb/ IIIa Receptor Antagonists has led to an improvement of combined clinical endpoints in patients with instable angina pectoris, who have undergone PTCA. For some patientgroups with elective PTCA a short-term and long-term advantage has been acknowledged. While an indication for Glycoprotein IIb/ IIIa Receptor Antagonists by interventional Angioplasty seems proven, the benefit of the application of this drug without Angioplasty is questioned/ under review. Since Glycoprotein IIb/ IIIa Receptor Antagonists are expensive, an evaluation is necessary of the patientgroups likely to benefit most.
The assessment focused on the effectiveness of Glycoprotein IIb/ IIIa Receptor Antagonists for Acute Coronary Syndrome.
A health-economic evaluation was carried out at the Institute for Health Economics/ University of Magdeburg (Prof. Dr. Stefan Felder).